Niraparib with androgen receptor‑axis‑targeted therapy in patients
Blog - Latest News
You are here: Home1 / Niraparib With Androgen Receptor-Axis-Targeted Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer: Safety And Pharmacokinetic Results From A Phase 1b Study (BEDIVERE)2 / Niraparib with androgen receptor‑axis‑targeted therapy in patients
Contact
Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572
Phone: (843) 839-1679
Fax: (843) 286-0119
Email:
info@curcmb.com
Recent Happenings
- Dr. Shore Presents Practice-Changing Data In Prostate Cancer / EMBARK points to potential new standard of care for high-risk BCR.
- AUA Chicago April 28 – May 1, 2023- Here We Come
- Perioperative Pembrolizumab Therapy In Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 And KEYNOTE-905/EV-303
- Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
Our Affiliates
Leave a Reply
Want to join the discussion?Feel free to contribute!